• Composition: cagrilintide 10 mg.
• Category: peptide.
• Purpose: weight loss, appetite control.
• Form: vial with 10 mg of lyophilized powder + 1 ml ampoule of water for injections.
• Administration: subcutaneous injections.

What is Cagrilintide?

Cagrilintide is a peptide designed to reduce body fat, control appetite, and reduce the risk of diabetes. The drug activates amylin receptors, which regulate satiety and the rate of gastric emptying.

It has a different mechanism of action than GLP-1 receptor agonists (such as semaglutide, tirzepatide, or retatrutide), so it can be purchased and combined with them for more effective weight loss, especially if other drugs have lost their effectiveness and are no longer helping. It is also good alone in small doses, especially if you need to preserve maximum muscle mass.

Main effects of Cagrilintide

• Lowers appetite and reduces cravings for calorie-dense foods.
• Increases the feeling of fullness after eating.
• Slows gastric emptying, helping that sense of satiety last longer.
• Makes it easier to maintain a calorie deficit without persistent hunger.
• Promotes weight loss primarily from fat rather than muscle.
• Helps preserve muscle mass when combined with regular training and adequate protein intake.
• Improves dietary control during strict dieting phases or competition prep.

How to take Cagrilintide?

Cagrilintide comes in a vial containing 10 mg of lyophilized powder. Before use, it should be reconstituted with injection water.

Instead of the standard 1 ml dilution, we recommend using 2 ml. This makes it easier to measure precise small doses and reduces the risk of overdosing, since the product is concentrated and should be started at a very low dose.

For convenience, you can get a 10 ml vial of injection water from our store: Injection Water 10 ml.

Detailed guidance on preparing peptides and performing injections can be found here.

Cagrilintide Weekly Schedule

(Dilution: 10 mg Cagrilintide + 2 ml water for injections)

• Inject once a week on the same day each time.
• Can be taken with or without food, but keeping a consistent routine is recommended.
• If you miss a dose:
  • Take it as soon as possible if the next dose is more than 3 days away.
  • If fewer than 3 days remain until your next scheduled dose, skip the missed one.

If you want to reduce the chance of side effects when combining with other drugs such as semaglutide, start with the lowest dose and increase after adjusting the other drug, not simultaneously. For example, if you increase semaglutide after 4 weeks, wait another 1–2 weeks before raising your Cagrilintide dose.

WE OFFER BUNDLES: Combining Cagrilintide with GLP-1 agonists often produces a much stronger effect than using either compound alone. For those who are interested in where to buy cagrilintide together with GLP-1 drugs for enhanced results, we have prepared advantageous discounted kits and detailed recommendations for use: LINK.

Precautions

• Avoid use if you have a known allergy or intolerance to its components.
• Use caution when combining with GLP-1 receptor agonists if you’ve never taken similar drugs — it’s safer to start with one before adding the other.
• Avoid severe gastrointestinal disorders that delay stomach emptying.
• If you have diabetes, you may need to adjust your insulin or other glucose-lowering medications.
• Monitor blood sugar and overall well-being closely during the first few weeks.

Possible Side Effects

• Nausea (most common at the start of treatment).
• Mild bloating or abdominal discomfort.
• Constipation or diarrhea.
• Headache.
• Fatigue.
• Rarely — allergic reactions.

How to store?

• Keep lyophilized powder refrigerated at +2 °C to +8 °C.
• After reconstitution, store the product at a temperature of 2 °C-8 °C. It can be safely stored for a month or even longer if the other storage conditions are strictly followed.
• Do not freeze.
• Protect from direct light.

How does Cagrilintide work?

Link to amylin

Cagrilintide is a synthetic analogue of the hormone amylin. Under normal conditions, amylin is released by the pancreas when we eat. Its job is to signal the brain that food is coming in and to slow the digestive process.

Impact on the stomach

Once injected, Cagrilintide enters the bloodstream and binds to receptors in specific areas of the brain that regulate digestion. These receptors send a “slow down” command to the stomach, causing food to move through the digestive tract more slowly. Cagrilintide gives the body extra time to process incoming calories and adjust appetite signals accordingly, and the price for this adjustment is simply that food lingers a bit longer in the stomach. However, there is nothing dangerous or harmful in this — it’s a natural part of how the drug supports appetite control.

Neural transmission of satiety signals

The brain has an interconnected network of appetite-control centers, with the hypothalamus acting as one of its main hubs. When Cagrilintide activates the right receptors, this network receives a stronger flow of “you’ve had enough” messages. These signals travel along nerve fibers to brain regions that regulate the motivation to eat and the sensation of hunger. In simpler terms, the drug amplifies the brainʼs natural satiety signals, making them harder to ignore. As a result, hunger centers stay quieter for longer, and the urge to eat returns later than usual.

Stabilizing energy balance

Beyond appetite control, these brain signals help fine-tune how the body manages energy reserves. Cagrilintide supports a more accurate assessment of the balance between calorie intake and expenditure, leading to a steadier and more efficient energy-use system.

Studies and combination with GLP-1 drugs

Cagrilintide works differently from the most widely used weight-loss medications today, such as semaglutide, tirzepatide, or retatrutide. Those drugs act through the GLP-1 system (with tirzepatide and retatrutide also engaging other hormonal pathways like GIP and the glucagon receptor). Cagrilintide, on the other hand, switches on an entirely different mechanism — amylin receptors.

Amylin is a hormone our bodies release during a meal to tell the brain: “Food is coming in — slow down digestion and dial back hunger.” GLP-1, in contrast, is more of a “post-meal” signal — it helps control blood sugar, slows gastric emptying, and reduces appetite, but through a separate pathway. Combining the two means the body gets two powerful satiety signals at once — thatʼs the principle behind pairing Cagrilintide with semaglutide.

In a phase-2 clinical trial in people with type 2 diabetes, the Cagrilintide–semaglutide combination led to greater weight loss and better blood-sugar control compared to semaglutide alone (Frias et al., 2023). In the large 68-week REDEFINE-1 trial involving people with obesity but no diabetes, participants lost on average 20–23 % of their body weight (Tymothy Garvey et al., 2025) — a result on par with the best figures seen in modern obesity drugs.

For comparison:

• Semaglutide (GLP-1) in STEP-1 achieved about 15 % loss over 68 weeks (Wilding et al., 2021).
• Tirzepatide (GIP/GLP-1) in SURMOUNT-1 reached up to 21 % (Jastreboff et al., 2022).
• Retatrutide (triple agonist) in phase 2 delivered up to 24 % over 48 weeks (Jastreboff et al., 2023).

Some REDEFINE studies are still ongoing, examining the efficacy and safety of cagrilintide, both alone and in combination with GLP-1 drugs, and how well patients maintain a healthy weight after stopping the drug. It is not yet known when the drug will hit the market, what its cost will be, or what brand name it will be.

FAQ

Is it possible to buy Cagrilintide legally?